ACHE and Alzheimer disease: Encouraged by the promising AChE inhibitory activity (67.8 % at 50 μmol/ L) of a coumarin–1,2,3-triazole-tyrosol hybrid, namely, 7-({1-[2-(4-hydroxyphenyl) ethyl]-1H-1,2,3-triazol-4-yl}methoxy)-4-methyl-2H-chromen-2-one (47), Bousada et al., in 2020, designed, synthesized, and evaluated tyrosol–1,2,3-triazole hybrids as a source of potent AChE inhibitors to treat AD.